Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028600 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00028600 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 60 participants.
The verdict
NCT00028600, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG melphalan
- BIOLOGICAL filgrastim
- BIOLOGICAL CD34+ cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028600
The ClinicalTrials.gov registry entry for NCT00028600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00028600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028600 about?
NCT00028600 is a clinical study titled "Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma". RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOS...
What is the current status of trial NCT00028600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-11. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00028600?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028600?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.